Inventor · disambiguated record
Kimberly A. Noonan
Also filed as: NOONAN KIMBERLY A · NOONAN KIMBERLY ANN
7 granted patents·18 pending applications·42 citations·filing 2006–2022
83Inventor score
Top patents by PatentIndex Score
25 records- 0196US9687510B2Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2015·Granted Jun 27, 2017·28 cites·15 claims
- 0295US10172887B2Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2017·Granted Jan 8, 2019·10 cites·19 claims
- 0386US11160830B2Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2018·Granted Nov 2, 2021·1 cites·13 claims
- 0482US10406178B2Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2017·Granted Sep 10, 2019·2 cites·20 claims
- 0581US2023000919A1Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 0677US11406666B2Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2019·Granted Aug 9, 2022·0 cites·41 claims
- 0777US2022016172A1Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2021·Application pending·0 cites
- 0874US11478548B2Marrow infiltrating lymphocytes (MILs) as a source of T-cells for chimeric antigen receptor (CAR) therapyUNIV JOHNS HOPKINS·Filed 2016·Granted Oct 25, 2022·1 cites·8 claims
- 0971US2023210990A1Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) thereapyUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 1070US2023016031A1Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) thereapyUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 1163US2020171089A1Use of Post-Transplant Cyclophosphamide Treated Allogenic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor ImmunityWINDMIL THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1263US2022257650A1MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPYWINDMIL THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1362US2011223146A1Methods for preparation and use of marrow infiltratng lymphoctyes (mils)UNIV JOHNS HOPKINS·Filed 2009·Application pending·0 cites
- 1460US2015320798A1Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor ImmunityUNIV JOHNS HOPKINS·Filed 2013·Application pending·0 cites
- 1560US2021154233A1MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPYWINDMIL THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1659US9468643B2PDE5 inhibitor compositions and methods for immunotherapyUNIV JOHNS HOPKINS·Filed 2014·Granted Oct 18, 2016·0 cites·16 claims
- 1759US2024238342A1A Vaccine Composition for Plasma Cell Disorders Including Multiple Myeloma and Methods to Induce Immunity Using SameMERIDIAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1859US2009074796A1Pde5 inhibitor compositions and methods for immunotherapyUNIV JOHNS HOPKINS·Filed 2006·Application pending·0 cites
- 1955US2017224691A1Pde inhibitors in immunotherapyUNIV JOHNS HOPKINS·Filed 2016·Application pending·0 cites
- 2051US2021338730A1Marrow Infiltrating Lymphocytes With Increased Clonality and Uses ThereofWINDMIL THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2151US2023100744A1Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched milsWINDMIL THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2249US2021000876A1Prostate Cancer Specific Marrow Infiltrating Lymphocytes and Uses ThereofWINDMIL THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2349US2022168350A1Lung Cancer Specific Marrow Infiltrating Lymphocytes and Uses ThereofWINDMIL THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2441US2018185434A1Immune checkpoint chimeric antigen receptors therapyUNIV JOHNS HOPKINS·Filed 2016·Application pending·0 cites
- 2540US2019330306A1Compositions and Methods for Modulating the Immune SystemWINDMIL THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →